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Abstract
Objective—Variation in the serotonin transporter gene (SLC6A4) promoter region has been
shown to influence depression in persons who have been exposed to a number of stressful life
events.
Method—We evaluated whether genetic variation in 5-HTTLPR, influences current depression,
lifetime history of depression and quantitative measures of depression in persons with chronic
psychotic disorders. This is an association study of a genetic variant with quantitative and
categorical definitions of depression conducted in the Southwest United States, Mexico, and Costa
Rica. We analyzed 260 subjects with a history of psychosis, from a sample of 129 families.
Results—We found that persons carrying at least one short allele had a statistically significant
increased lifetime risk for depressive syndromes (p<.02, Odds Ratio=2.18, 95% CI=1.10–4.20).
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Conclusion—The “ss” or “sl” genotype at the 5-HTTLPR promoter polymorphic locus increases
the risk of psychotic individuals to develop major depression during the course of their illness.
Keywords
Serotonin transporter polymorphism; depression; psychosis
Introduction
The serotonin transporter protein plays a crucial role in regulating the intensity and duration
of serotonergic signaling at synapses (1) and has been a target for many psychiatric drugs
(2–4). This protein is encoded by a single gene (SLC6A4, Locus Link ID: 6532), which has
been mapped to chromosome 17q11.1-q12 (5). There are at least two polymorphic variants
that play a role in differential expression of the SLC6A4 gene. Several studies have analyzed
the role of these variants in anxiety and depression (6–11). Two of these studies (Caspi et
al., 10 and Kendler et al. 11) studied the association of an insertion/deletion (s/l) variant in
the promoter region of this gene with depression in the context of stressful life events. In
both of these studies, variation in the promoter region of the serotonin transporter gene was
shown to influence depression in persons who have been exposed to a number of stressful
life events. Alleles with the deletion are coded as “s” for short form of the allele, and those
with the insertion are coded “l” for long form. Individuals can be genotyped as ss, sl, or ll
(carrying two copies of the deletion, one copy of the deletion, or no copies of the deletion,
respectively).
Caspi et al., 2003 (10) found that current depressive symptoms, diagnosable depression and
suicidality in individuals were associated with having one or two copies of the “s” allele, but
only in the context of stressful life events. Kendler et al., 20065 (11) were able to partially
replicate this finding, showing in an independent sample that individuals with two s alleles
showed an increased risk of depression in the last year, in the context of stressful life events.
Many other researchers have recently contributed to this area of research (12–15). The s
allele has been reported to effect the expression of the SLC6A4 gene, resulting in decreased
expression of the serotonin transporter (5-HTT) protein (16). Hranilovic et al., 2004 (17)
studied differences in expression between persons with ss, sl, or ll genotypes and found that
the s allele acted in a dominant fashion; having one or two copies of the s allele resulted in
reduced expression of 5-HTT of 27% and 30% respectively, compared to expression in
individuals with the ll genotype. Due to the effects of this genetic variation on expression,
and the known role of serotonin in a variety of disorders, variation in the SLC6A4 gene has
been suggested as potentially underlying a number of psychiatric disorders (18–24).
A potential role of the serotonin transporter protein in schizophrenia was suggested by a
study showing that there was decreased paroxetine binding to the 5-HTT protein in the
hippocampus of subjects with schizophrenia (25). Yet, direct association of the 5-HTTLPR
S/L genotype and the categorical phenotype of schizophrenia have been for the most part
negative (26), (27), (28). One potential consequence of carrying the S polymorphic variant
might be that it might act as a modifier for the course of illness in persons who have a
primary psychotic disorder by leading to increased depressive features during the person’s
lifetime. Depressive features, including depressive syndromes and symptoms commonly
associated with depression, such as suicidality, are common in schizophrenics, with some
studies suggesting that at least 25% of schizophrenic subjects may experience comorbid
depression (29). The 1996 study of Dean and colleagues found that decreased paroxetine
binding to the 5-HTT protein was most apparent in individuals who had committed suicide
(30). To our knowledge, there has been only one study that has tested the hypothesis that the
S variant of the 5-HTTLPR might play a direct role in increasing risk of depression in
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persons who suffer from psychotic disorders. Golimbet and colleagues found that patients
with the SS genotype scored significantly higher on Guilt Feelings and Depression Items as
compared with those of the LL genotype (31).
Different studies (32) suggest that the presence or absence of the s allele in the promoter
region of the SLC6A4 gene is a key mediator of the brain’s adaptative response to stress
(33) and the study of Golimbet et al (31) suggests that it plays a potentially similar role in
persons with schizophrenia. Schizophrenic subjects (or subjects with chronic psychosis)
experience a higher number of adverse life events, in comparison to the general population,
with increased histories of unemployment, homelessness, difficulties with marital
relationships, and medical and legal problems (34). We studied subjects recruited from a
genetic study of schizophrenia who had a clinical (hospital) diagnosis of schizophrenia. We
argue that having a chronic psychotic disorder could function as a major adverse life event,
and that in this context, variation of the 5-HTTPR would predict risk of lifetime and current
depression. We hypothesized that in these subjects, those with at least one copy of the 5-
HTTPR “s” allele would have a greater history of lifetime and current depression than those
subjects who had an “l/l” genotype. We also tested for interaction between lifetime
psychosis culled from a recently developed instrument called the Lifetime Dimensions of
Psychosis Scale (35) and depression, based on “s” and “l” genotype. Although some recent
studies have suggested that finer genotyping of the “l” allele can yield additional
information, our budget did not allow us to explore the “tri-allelic” hypothesis. We therefore
limit this study to the effects of the “s” and “l” variants on depression in the context of
psychosis.
Aims of the study
Our aims were to examine this association using three theoretically correlated definitions of
depression: i) a history of lifetime depressive syndrome or episode based on categorical
diagnosis, ii) a current depressive syndrome or episode at the time of interview (“last 30
days”) and iii) a dimensional measure of lifetime depression.
Material and methods
Subjects
Ascertainment: Subjects were originally recruited for a family based linkage study of
schizophrenia and schizoaffective disorder conducted in Mexico, the Southwest United
States, Guatemala and Costa Rica (36). Families were eligible for study if they had at least
two siblings with hospital or clinic diagnoses of schizophrenia or schizoaffective disorder. In
each family, all subjects with a history of psychotic disorder, as determined through family
review using the
Family Interview for Genetic Studies (FIGS), underwent the full diagnostic and best
estimate consensus process. Two hundred and sixty subjects (from 129 families) had a
lifetime history of psychosis. The mode of subjects per family was 2 (minimum 1, maximum
6). Sixty-one percent of these subjects were male. The mean age at time of interview was
37.9 (standard deviation = 11.68). Out of the 260 individuals 155 had lifetime history of
depressive syndrome. The genotype distribution was “ss” 95 (36%), “sl” 116 (45%) and “ll”
49 (19%). Forty-seven percent of the subjects were recruited in Mexico, 39% were from the
Southwest United States, and 16% were from Central America. All subjects were of Latino
ancestry.
In a set of secondary analyses, using different methodology to ensure independence of
subjects analyzed in this current paper, only one subject per family (the first subject with a
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hospital diagnosis of schizophrenia or schizoaffective disorder recruited in each family) was
used for the statistical analyses presented below. One hundred and twenty-nine subjects
were included in these analyses: 60 (47%) were recruited from sites in Mexico (32 from
Monterrey, 28 from Mexico City), 48 (39%) were recruited from sites in the Southwest
United States (26 from San Antonio, 14 from Los Angeles, 8 from San Diego), and 21
(16%) from Costa Rica. This secondary sample consisted of fifty-three females and seventy-
six males with a mean age at participation of 37.45 years (standard deviation +/− 10.37).
Demographic information for this set of individuals is presented in Table 1.
Diagnostic Process: Each subject was interviewed in their native language, by a psychiatrist
fluent in that language, using the DIGS (Diagnostic Interview for Genetic Studies) (37). A
consensus best estimate review process, utilizing direct interview with the patient (DIGS
interview), FIGS interview with a close relative of the patient, and review of any available
medical or psychiatric records, was utilized to arrive at final categorical diagnoses, using
DSM IV criteria. Details of the instrument development, standardization, training and
reliability of the diagnostic process can be found elsewhere (37). Although each subject
study had an outpatient or inpatient diagnosis of schizophrenia or schizoaffective, hospitals
in the United States, Mexico, and Costa Rica often use different clinical diagnostic systems
which are not always compatible, and previous studies in the Latino population have shown
that a more rigorous, standardized diagnostic process often reveals a spectrum of closely
related psychotic disorders can receive hospital diagnoses of schizophrenia or
schizoaffective disorder (38). All subjects had, according to best estimate consensus, a
history of psychosis, as defined by Criteria A for DSM-IV Schizophrenia. Specific
consensus DSM-IV diagnoses of the full sample of psychotic subjects were as follows:
Schizophrenia (201), Schizoaffective Disorder Bipolar Type (27), Schizoaffective
Depressed Type (9), Bipolar Disorder (9), Psychotic Disorder Not Otherwise Specified (9),
Major Depressive Disorder with Psychosis (4), and Psychosis secondary to a Medical
Condition (1). In the smaller sample of one person per family, the breakdown of diagnoses
was as follows: Schizophrenia (105), Schizoaffective Disorder (18), Psychosis Not
Otherwise Specified (2), Bipolar Disorder (2), Major Depressive Disorder with psychosis
(2).
Measures of Depression
Categorical measures: During the best estimate diagnostic procedure, diagnosticians
arrived at consensus for whether or not each subject had ever had a full major depressive
syndrome (as defined by criteria A for Major Depressive Episode in the DSM-IV). Lifetime
history and current history of having a full major depressive syndrome or episode were the
two categorical variables our primary categorical variable tested in the current study. For
defining current syndrome or episode, presence or absence was determined by reviewing the
current symptoms of depression and their duration, as captured in the DIGS.
Dimensional measures: The Lifetime Dimensions of Psychosis Scale (LDPS) includes
measures of depression, and is designed for use in studying subjects with psychotic
disorders (35). The LDPS is designed for experienced clinicians who have access to
comprehensive clinical information, including semi-structured diagnostic interviews,
psychiatric records, and family history reports. To generate a dimensional index of lifetime
depression severity, we multiplied the severity score (from 0 to 4) with the lifetime duration
score (from 0 to 4) to arrive at a variable for depression that could range from 0 to 16. The
distribution for this index for the complete sample are shown in Figure 1. Secondary
dimensional analyses for depressive features included duration of depression, severity of
depression, and the number of symptoms of depression. For psychosis, we utilized the P-1
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(any delusions) and P-3 (any hallucinations) dimensions from the LDPS, with variables
ranging from 0 to 16 for each of these dimensions.
Genotyping
Peripheral blood was collected to create lymphoblastic cell lines. Genomic DNA was
extracted from transformed lymphocytes by a standard procedure as described in Lahiri and
Nurnberger (39). PCR for the 5-HTTLPR polymorphism was performed in a total volume of
15 μl containing 1.8 mM MgCl2, 200 mM of each dATP, dCTP and dTTP, 100 mM each of
dGTP, and 7-deaza-dGTP, 0.96 units of AmpliTaq Gold polymerase (AmpliTaq Gold;
Perkin Elmer, Norwalk, CT, USA), 1.3 μM primers (5′GGC GTT GCC GCT CTG AAT
TGC and 5′ GAG GGA CTG AGC TGG ACA ACC CAC) (40) and 150 ng of genomic
DNA. After an initial 10-minutes denaturation step at 95°C, 45 cycles were performed
consisting of 30 s at 95°C, 30 s at 61°C and 1 min at 72°C, followed by a final step of 7 min
at 72°C. PCR products were separated on 2% high-melt agarose gel and visualized by UV
after ethidium bromide staining. Genotyping was performed in Mexico City and scoring of
alleles was performed by technicians bind to diagnostic status and clinical history of the
subjects.
Statistical analysis
Campos-Sánchez et al (41) independently analyzed the genetic relationships of subjects
collected in Costa Rica, Mexico City, and the Southwest United States, and found that they
constitute a group with similar ancestral DNA characteristics and can be reasonably
analyzed as a homogeneous group for purposes of combined analysis. Subjects were divided
into two groups based on presence or absence of an “S” genotype: 49 subjects were in
Group 1 (LL genotype), and the remaining 211 were classified as Group 2 (116 who had an
SL genotype and 95 who had an SS genotype). Groups were clustered in this manner, since
the S genotype is known to function in a dominant manner with regard to suppression of
transcription of the 5-HTT gene (7). To test for possible stratification between these two
groups, we also analyzed genotype frequencies for 20 markers genotyped in these same
subjects. The 20 markers were chosen at random from a set of markers previously genotyped
by the Center for Inherited Disease Research (36), spanning the genome and included the
following microsatellites: D1S1588, D1S1663, D1S2141, D3S4523, D3S2427, D4S1644,
D5S2849, D5S820, D5S211, D7S3046, D7S2204, D7S3058, D10S1225, D10S1432,
D11S2002, D14S587, D15S1507, D17S1301, D18S843, D22S445. Genotypes appearing
less than five times were collapsed into one genotype class. Chi-square analyses were
performed to evaluate whether there were statistically significant differences (p<.05) for the
genotype frequencies for the “ss/sl” group and the “ll” group of subjects at any of these
markers.
LDPS score of items DE-1 was tested for normal distribution in the sample of 129 (one
psychotic subject per family). Duration x severity of symptoms was not normally distributed
in the whole sample. However it was normally distributed (p>0.05) in the group of
individuals with life-time history of depression (Shapiro-Wilk and Kolmogorov-Smirnov
Test with Lilliefors significance correction).
For the full sample (all 260 subjects with a history of psychosis), we analyzed whether a
lifetime history of depressive syndrome or episode was associated with the 5-HTTLPR S/L
genotype. For these analyses, descriptive statistics were calculated using SAS software (42).
Because individual subject data were nested within families, hierarchical regression methods
were used to correct for potential type-1 error due to grouped family data. A multilevel
logistic regression model was carried out using MIWin (43) Software. A genotype variable
was created where subjects possessing an SS or SL genotype were coded as 1, and those
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with LL were coded as 0. This dummy variable was used as a predictor of a dichotomous
depression variable. A 2nd model was run adjusting for gender and age.
This same analysis (lifetime history of depressive episode or syndrome) as well as several
additional analyses (current depressive episode/syndrome, severity and duration of LDPS
depression scores) were performed on the subset of one subject per family (n=129 subjects
with a history of psychosis). Age of subjects can have an effect on the LDPS duration score
and gender is a known factor in differential risk of lifetime depression (44). Therefore we
compared the two genotype groups (Group 1 and 2) with regard to these two variables. The
percentage of females in Group 1 (LL genotype) was slightly higher, and the age of Group 2
(SL or SS genotype) was slightly higher, however these differences were not statistically
significant between groups for either of these two variables (age (p=0.197) and gender
(p=0.516), Table 1). Chi square scores were calculated to evaluate association between the
genotype and lifetime history of depressive syndrome and current depressive syndrome
(categorical diagnoses). To test for association of genotype groups and dimensional
measures of depression, we utilized the ANOVA least square means statistical test, covering
for age and gender. In all of the tests, the criterion for significance was set atp<0.05.
Corrections for multiple testing were not utilized, as the measures of depression we were
testing are most likely very highly correlated and are not independent factors. Analyses were
conducted with SPSS 15 software. We also tested the hypothesis that genotype (ss or sl,
versus ll) would interact with the dimension of lifetime psychosis, to cause increased
depressive symptoms. Using the dimensions of lifetime delusions and lifetime hallucinations
(P-1 and P-3 from the LDPS), we tested for possible correlation between each of these
psychotic symptoms and the LDPS dimension of lifetime depression. Correlations were
tested independently for the ss/sl group and the ll genotype group.
Results
For the full sample of 260 subjects with psychosis, the null model (no predictors) indicates
that there was no significant level 2 variation in the outcome variable (lifetime depression)
(level 2 variance = .26, standard error = .29, p 0 .92). This indicates that variation in lifetime
depression was not influenced by familiar clustering in this sample. Sixty percent of the
subjects had had a lifetime history of at least one full depressive episode or syndrome. The
5-HTTLPR marker used for this analysis was in Hardy-Weinberg equilibrium. The
regression coefficient for the genotype variable was statistically significant (b = .73 (.34), p
< .02; OR = 2.07, 95% CI = 1.14 – 3.95) indicating that those possessing either the SS or SL
genotype were 2.07 times more likely to be categorized as having had a full syndrome/
episode of depression during their lifetime. In the adjusted model, the regression coefficient
for the genotype variable not only remains significant but increases slightly (b = .78 (.36), p
< .02; OR = 2.18, 95% CI = 1.10 – 4.20). For the sample of 129 individuals with history of
psychosis (one per family), the majority suffered a full episode or syndrome of major
depression during their lifetime (77 individuals, 60% of the total sample). We found a
significant association between the SS or SL genotype (genotype group 2) and lifetime
history of depression (x2=4.211, df=1, p=0.040, Table 1. In those 77 individuals who
developed a depressive syndrome at some point in their life, almost all subjects developed
depressive syndromes in the same year or at later age than the onset of psychosis (68,
(92%)). As our hypothesis was that psychosis is the primary stressor, we also analyzed the
subjects, limited to only those subjects where depression occurred during the same year or
after the onset of psychosis; the results still showed that having an SS or SL genotype
(Group 2) was significantly associated to having had a history of a major depressive
syndrome (p=0.029). We also analyzed this association for the subset of schizophrenic
individuals. These results still showed that having an SS or SL genotype was significantly
associated to history of a major depressive syndrome. We replicated this analysis in a
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subsample were the second recruited subject of each family was assessed (103 individuals).
Fifty three subjects had history of depressive syndrome, 83 had “ss/sl” genotype and 20 “ll”
genotype. The association of “ss/sl” genotype with depression remained significant (x2=4.5,
p=.32).
In terms of current depression, 19 of the 129 individuals met criteria for a full syndrome of
depression (14.7% of the total sample). Interestingly, none of the individuals with an LL
genotype had a current depressive syndrome. Having an SS or SL genotype was
significantly associated with presence of a current major depressive syndrome (X2=6.39,
p=0.012, Table 1).
Individuals with genotype SS or SL genotype had significantly elevated scores for the LDPS
dimension of depression (LDPS DE 1 duration x severity, p=.046), as well as the
dimensional scores for lifetime duration of depressive features (LDPS DE1 duration, p=.
050), lifetime severity of depressive symptoms (LDPS DE-1 severity, p=.050), and
maximum number of depressive symptoms during their lifetime (LDPS DE-2 score, p=.
019). The LDPS scale was not useful as a dimensional variable for subjects who had never
had a history of a full depressive syndrome, as variance in those subjects was limited to
either a 0 or a 1 (LDPS DE1 duration X severity). Within subjects that had a positive history
of depressive syndromes, this dimension showed a normal distribution curve, as shown in
Figure 1.
As a secondary analysis, Figures 2 and 3 show the breakdown of the categorical and
dimensional measures, with relation to the three distinct genotype groups (LL, SL, and SS).
As expected, persons with one or two copies of the S allele showed similar rates of
depression (both categorically and dimensionally, which is consistent with previous
literature suggesting the “s” allele acts in a dominant manner with regard to effecting RNA
expression of the transporter gene. On all 6 measures, persons with an SS versus and SL
genotype showed no statistical difference in terms of lifetime or current depression (0.40<p<
0.91).
In terms of lifetime dimensional measures of psychosis and depression, we found positive
correlation between delusions and depression (p=.028) and hallucinations and depression
(p=.029) in the SS/SL group (Figure 4). In the LL group there was no correlation between
either delusions and depression or hallucinations and depression.
Tests for possible stratification in the 20 random microsatellite markers yielded only 2
markers which showed genotype frequency differences at a level of p< .05 between the two
groups of subjects (Group 1 being individuals with an ss or sl genotype, and Group 2 being
individuals with an ll genotype). This is slightly more than would be predicted by chance
(1/20) if there were no stratification between these two groups.
Discussion
Patients with hospital diagnoses of schizophrenia and schizoaffective disorder are at great
risk for lifetime history of a full depressive syndrome or episode. In the full sample, sixty
percent of the subjects with a history of psychosis also had a history of depressive episodes
or syndromes, which is consistent with studies that have investigated the extent of
depression in subjects with chronic psychotic disorders (45). Within the group of 129
subjects (one per family) with a strict, post best estimate consensus diagnosis of
Schizophrenia, 45% had a lifetime history of major depressive syndromes, consistent with
previous studies (46). This high rate of depression may be a factor in the high rates of
suicide attempts and suicidal completion in people who suffer from schizophrenia, which
may run as high as 20%–40% and 5–13% respectively (47).
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In terms of current depression, the rates are still above most epidemiologic reports culled
from the general population (48). Of special note, in our sample all of the subjects with a
current depressive syndrome were subjects who had either one or two copies of the “S”
allele of 5HTT-PR polymorphism.
Our results are consistent with the dominant model suggested by Hranilovic et al. (17) and
showed in both the full sample analysis and the smaller (one per family analysis) that having
an “ss” or “sl” genotype increased risk of lifetime depression. Interestingly, we also show
that the lifetime dimension (duration x severity) of delusions and hallucinations both
correlate with increased lifetime depression, but only in persons with an “ss” or “sl”
genotype. Those with an “ll” genotype did not show this correlation between psychosis and
depression which was also replicated in the subsample of second recruited subject for each
family. We therefore conclude that in our sample, the “s” variant confers increased risk for
depression in the context of psychotic illness.
Interestingly, we found, when looking at dimensional ratings, that carriers of an S allele
showed longer duration of depression during their lifetime, greater severity of depression
when it did occur, and a greater number of depressive symptoms during the worst episode.
Although these aspects of depression might all be strongly correlated (for instance it is
known that lifetime prevalence of depressive episodes correlates strongly with presence or
absence of a current depressive episode), we find it interesting that the effects of having an S
allele appear to affect severity as well as duration of depressive symptoms within persons
who have a chronic disorder. These findings are consistent, in a new sample and new type of
population, with the findings of Golimbet et al (31), who also showed, in patients with
chronic psychosis, that increased rates of several depressive symptoms was associated with
having an SS or SL genotype. Moreover, we have shown that not only symptoms but full
depressive syndromes are associated with patients with chronic psychosis who have an SS or
SL genotype and that this association exists for both current and past episodes of depression.
An increased number of adverse life events were a necessary condition in order to see a role
of this polymorphism in predicting depression in both the Caspi et al (10) and Kendler et al
(11) studies, which studied people from general population samples. We hypothesized that
chronic psychosis might itself act as a “stressor” which might interact with the s/l serotonin
transporter variant to increase depression in persons with at least one copy of the “s” variant.
Since we did not have information on life stressors, we could not test the hypothesis that
specific life stressors interact with this genotype to increase depression. It is possible that
there might be a correlation between life stressors and the duration of severity of psychotic
symptoms, however this is not directly addressable with our data.
One can hypothesize several potential pathways which might explain the high rates of
depression in persons with a psychotic disorder. Lack of personal security, living conditions
potentially harmful to the patients’ psychological well-being, persecution and
discrimination, bad peer relationships and unemployment are all potential sequelae of
problems of interaction between the psychotic individual and his/her environment. For
persons whose psychosis carries a paranoid element, as argued by Birchwood et al, the
presumed threat from persecutors to the individual’s well being may be sufficient to trigger
depression and fear (49). For those patients who have sufficient insight to be aware of their
illness and how it impacts their life, awareness of illness may be a direct trigger for a
potentially dysphoric response. Post-psychotic depression, for instance, is a common
occurrence in persons who are treated for first-break psychosis (50).
In understanding why some persons are more at risk than others, we conclude that the
5HTTPR polymorphism explains some of this variance. Whether one conceives of the LL
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genotype as protective against development of full depressive episodes, or views the SS or
SL genotype as a risk factor, our current results support a role for this variant in the course
of illness (i.e. likelihood of developing secondary depression) of those with psychotic
disorders.
Our study drew from a sample that was specially selected because the subjects had familial
psychotic disorder. A limitation is that, although the major risk factor for schizophrenia is a
family history, most schizophrenic subjects do not have a known family member with
schizophrenia or chronic psychosis. Our study cannot be generalized to all subjects with
schizophrenia, but it can be generalized to persons with familial forms of chronic psychotic
conditions. In this sense, our study complements the findings of Golimbet et al (31), who
drew from a more general sample of schizophrenic subjects. Another limitation of the study
is that our analyses were based on comparison between two groups (ss/sl group and ll group)
and there might be underlying stratification between these groups. In finding that only 2 of
20 randomly chosen microsatellites showed statistical differences in gene frequencies
between the two groups, we can say that stratification in this sample is minimal.
Nevertheless, our results should be interpreted with caution unless replicated in similar or
larger samples. Family based association tests are one way to overcome the effects of
potential stratification, but there were not enough informative families in our sample to test
this. Another limitation of the current study is that we were not able to do additional
genotyping beyond the s/l variant. Zalsman et al 53 have recently shown that a third
polymorphism in he 5HTT gene interacts with the S/L 5HTTPR variant, and this may lead
to finer delineation of relative expression of the 5HTT gene. Although this is an interesting
development in the study of the 5HTT gene, our limited funding limited us to studying
hypotheses generated from the studies of Caspi et al (10), Kendler et al (11), and Golimbet
et al. (31), which based their analyses on the S/L variation. In future studies, evaluation of
all polymorphisms in the 5HTT gene will be useful in order to even more carefully evaluate
how genetic variation in this gene affects the onset and course of depression in persons both
with and without psychotic disorders.
How to classify the genotype groups is a question that has been addressed differently in the
literature. Based on studies suggesting the “S” allele acts in a dominant fashion, we chose to
do our primary analysis by clustering the SS and SL genoypes together, for a combined SS/
SL group, which is the group Caspi et al (10) found to be associated with increased risk of
depressive symptoms. All of our analyses that grouped the SS and SL alleles showed
significant differences, as those found by Caspi et al (10). Our secondary analyses did not
show significant differences between SS and SL genotypes with regard to depressive
symptoms. In the Golimbet study (31), as in the Kendler study (11), the significant
comparison was between persons with an SS genotype and persons with an LL genotype.
We did find significant differences between those with an SS and those with an LL genotype
for current depressive syndrome (x2=4.38, p=0.037), in the expected direction (SS
genotypes increasing the risk of current depression). Although we did not find significant
differences between the SS and LL genotyped subjects for the other dimensions of
depression, this may have been due to the smaller sample size used when the SL subjects are
removed from the analysis.
An advantage of the current study is that we know these subjects have, in all likelihood, a
genetic form of psychosis. It has long been shown that, in families of persons with
schizophrenics, one often sees relatives with schizoaffective disorder (51); why one person
develops schizophrenia and another develops schizoaffective disorder has been an open
question, although some have hypothesized that this may be in part due to modifying genes
(52). Given that, it is interesting to consider that our study provides evidence that the
5HTTPR polymorphism may actually act as a modifier in genetic forms of psychosis. For
Contreras et al. Page 9
Acta Psychiatr Scand. Author manuscript; available in PMC 2014 March 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
instance, according to the DSMIV, the difference between schizoaffective depressed
disorder and schizophrenia, when a subject has had depression in the context of a chronic
psychosis, is the relative duration of the depressive syndromes to the psychotic symptoms.
Indeed, in the current study, persons with the LL variant ended up with a consensus
diagnosis of schizophrenia (rather than schizoaffective disorder) more often than did those
who had an SS or SL variant. Given that our study shows that this polymorphism is
associated with increased severity and duration of depressive symptoms, it should be
considered a possible modifier for genetic forms of psychosis.
Although, with only this and the study of Golimbet et al (31) showing the association of the
S variant and increased symptoms of depression in persons with chronic psychosis, one must
be cautious about generalizations, these results do offer some potential lines for further
research. Genotyping of the 5HTTPR may be a potential clinical tool when treating persons
with new onset psychosis or chronic psychosis. For instance, having one or more copy of the
S allele might suggest that treatment strategies might include antidepressants or atypical
antipsychotic medications which can help compensate for the decreased expression of the
5HTT gene and, secondarily, the increased risk of developing secondary depression.
Carefully controlled, prospective medication trials will be necessary to test this. Of special
interest will be prospective studies in persons with chronic psychosis who have not yet
developed depression. Given the high rates of suicidality and suicide attempts in persons
with schizophrenia (46–48) and the likely high consequences of comorbid depression on top
of a chronic psychotic disorder, additional studies of how to decrease depressive
comorbidity in persons with schizophrenia may help us to substantially improve our
treatment paradigms for persons who suffer from and are trying to overcome the
consequences of psychotic conditions.
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Significant Outcomes
• The 5-HTTLPR “s” variant increases risk for depression in psychotic illness.
• This polymorphism is associated with increased severity and duration of
depressive symptoms.
Limitations
• These analyses were based on comparison between two groups (ss/sl and ll) and
there might be underlying stratification.
• We were not able to explore the “tri-allelic” variation of this polymorphism.
• Since we did not have life stressors scales, we could not test the hypothesis that
specific life stressors interact with this genotype to increase depression.
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Figure 1.
Distribution (LDPS)
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Figure 2.
LDPS least square means by genotype
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Figure 3.
Rates of Depression by Genotype
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Figure 4.
Correlation between depression and psychosis in the SS/SL group.
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Table 1
Demographic and clinical characteristics of participants, by e
LL SS & SL Statistic
Sample Size 28 101
Age^ 35.21 (1.7) 38.08 (1.1) F[1,127]=1.68, p=.197
% Female 46.43 39.60 χ2[1,127]=0.422, p=.516
% Life Time Depression 42.86 64.36 χ2[1,127]=4.211, p=.040
% Current Depression 0.00 19.39 χ2[1,127]=6.393, p=.012
LDPS Duration of Depression# 1.40 (0.2) 1.93 (0.1) F[1,123]=3.92, p=.050
LDPS Severity of Depression# 1.49 (0.3) 2.08 (0.1) F[1,123]=3.90, p=0.050
LDPS Duration * Severity# 3.64 (0.9) 5.61 (0.5) F[1,123]=4.06, p=0.046
LDPS Number of Symptoms# 3.39 (0.6) 4.97 (0.3) F[1,123]=5.63, p=0.019
^
 mean (standard error);
#
 least square means (standard error) while covering for age and gender
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